Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2016

View Archived Issues

Cancer Research Technology announces ENPP2 inhibitors

Rugen Holdings reports NR2B receptor antagonists

USPI reports successful completion of preclinical testing of PROACT-D

Galectin's GR-MD-02 doesn't perform well enough in phase IIa trial

Mitsubishi Tanabe files application in Japan for combination drug for type 2 diabetes mellitus

Lundbeck updates progress of second quarter 2016

Novartis presents novel series of small molecule CSN5 inhibitors for the treatment of cancer

Suven describes novel series of amides as 5-HT4 receptor agonists for the treatment of AD

Immunovaccine releases new data from phase I/Ib study of DPX-Survivac in ovarian cancer

Sorrento Therapeutics discloses anti-HER2 antibody-anthracycline conjugates

FDA clears IND for phase I trial of DeuteRx's DRX-065

Immunophotonics doses first patient in trial of inCVAX

U.S. government contract supports Chembio Diagnostics' development of Zika point-of-care tests

Janssen describes novel tau protein PET imaging ligand [18F]JNJ-311 at ACS

BioLineRx enters joint venture with I-Bridge Capital

Factor IXa inhibitor CFM-184 shows anticoagulant potential

Positive results for Armetheon's phase I trial of tecarfarin

Lee's Pharmaceutical and Beijing Shenogen Pharma collaborate on combination product in China

Neuroderm starts enrollment in phase III trial of ND-0612L

FDA grants fast track status to Mallinckrodt's Synacthen Depot

Researchers from Genentech identify novel potent and selective NIK inhibitors

EXPAND phase III study meets its primary endpoint

Biotie Therapies' BTT-1023 receives FDA orphan drug designation

FDA grants orphan drug designation to TG Therapeutics' ublituximab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...